Abstract
AL102 is a potent, orally available, selective gamma secretase inhibitor (GSI) under investigation as an antineoplastic agent. GSIs have antitumor activity against DT, including AL101 (2 confirmed PRs >3.5 years and >1 year; 1 stable disease for 1 year). There remains an unmet need for effective systemic therapy in DT, associated with durable tolerability, tumor regression, and symptom improvement.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
